The benefits of immunotherapy and the impact of available therapies for metastatic melanoma on the clinical outcome of patients in the Unified Health System (SUS). Research, Society and Development, [S. l.], v. 14, n. 5, p. e5014548809, 2025. DOI: 10.33448/rsd-v14i5.48809. Disponível em: https://ojs34.rsdjournal.org/index.php/rsd/article/view/48809. Acesso em: 28 jun. 2025.